# Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

> **NCT03836482** · NA · RECRUITING · sponsor: **SeaStar Medical** · enrollment: 20 (estimated)

## Conditions studied

- Acute on Chronic Systolic Congestive Heart Failure
- Cardiorenal Syndrome

## Interventions

- **DEVICE:** Selective Cytopheretic Device

## Key facts

- **NCT ID:** NCT03836482
- **Lead sponsor:** SeaStar Medical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-02
- **Primary completion:** 2027-02
- **Final completion:** 2027-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- National Heart, Lung, and Blood Institute (NHLBI)
- University of Michigan
- Innovative BioTherapies (IBT)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836482, "Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT03836482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*